Volume 58, Issue 2, Pages (August 2000)

Slides:

Advertisements

Similar presentations

Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages

Advertisements

Volume 69, Issue 1, Pages (January 2006)

Management of IgA nephropathy: Evidence-based recommendations

Volume 54, Issue 2, Pages (August 1998)

Volume 64, Issue 1, Pages (July 2003)

Inflammatory cytokines in acute renal failure

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig

Yiping Wang, Yuet-Ching Tay, David C.H. Harris Kidney International

G protein β3 subunit C825T polymorphism in primary IgA nephropathy

Volume 56, Issue 2, Pages (August 1999)

Volume 85, Issue 3, Pages (March 2014)

Volume 59, Issue 3, Pages (March 2001)

Volume 54, Issue 5, Pages (November 1998)

Volume 92, Issue 4, Pages (October 2017)

Volume 71, Issue 5, Pages (March 2007)

Volume 67, Issue 2, Pages (February 2005)

Volume 93, Issue 1, Pages (January 2018)

Volume 119, Issue 4, Pages (October 2000)

Volume 71, Issue 6, Pages (March 2007)

Volume 75, Issue 1, Pages (January 2009)

Volume 82, Issue 3, Pages (August 2012)

Blood pressure targets in hemodialysis patients

Frank Eitner, Jürgen Floege Kidney International

Volume 76, Issue 5, Pages (September 2009)

Ring-like calcifications of the kidney

Effect of anemia and renal cytokine production on erythropoietin production during blood-stage malaria Kai-Hsin Chang, Mary M. Stevenson Kidney International

Watermelon stomach in a uremia patient

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Genetic Analysis of Male Pattern Baldness and the 5α-Reductase Genes

Volume 64, Issue 3, Pages (September 2003)

S. Alexiou-Daniel, A. Stylianakis, A. Papoutsi, I. Zorbas, A. Papa, A

Volume 61, Issue 6, Pages (June 2002)

A.K.I. Kuroki, Masayuki Iyoda, Takanori Shibata, Tetsuzo Sugisaki

Volume 60, Issue 3, Pages (September 2001)

Masahide Yazaki, Sandra A. Farrell, Merrill D. Benson

Volume 65, Issue 4, Pages (April 2004)

Cheng-Yu Long, M. D. , Chun-Shuo Hsu, M. D. , Pei-Lin Shao, M. S

Volume 69, Issue 8, Pages (April 2006)

Volume 80, Issue 3, Pages (August 2011)

Volume 82, Issue 7, Pages (October 2012)

Volume 56, Issue 4, Pages (October 1999)

Analytical Evaluation of Primer Engineered Multiplex Polymerase Chain Reaction– Restriction Fragment Length Polymorphism for Detection of Factor V Leiden.

Daily nocturnal home hemodialysis

Racial differences in survival of patients on dialysis

Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass

Volume 61, Issue 5, Pages (May 2002)

Low triiodothyronine and survival in end-stage renal disease

Volume 56, Pages S84-S87 (November 1999)

Volume 80, Issue 10, Pages (November 2011)

Glucose transporter (GLUT1) allele (XbaI–) associated with nephropathy in non-insulin- dependent diabetes mellitus Zhi-Hong Liu, Tian-Jun Guan, Zhao-Hong.

Volume 56, Issue 1, Pages (July 1999)

Volume 69, Issue 10, Pages (May 2006)

Typing of Clostridium difficile

Volume 62, Issue 3, Pages (September 2002)

Charles A. Herzog Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 86, Issue 5, Pages (November 2014)

Volume 67, Issue 1, Pages (January 2005)

Toward a B-cell signature of tolerance?

Sundararaman Swaminathan, Matthew D. Griffin Kidney International

Volume 86, Issue 2, Pages (August 2014)

Adiponectin: good, bad, or just plain ugly?

Volume 70, Issue 10, Pages (November 2006)

Volume 63, Issue 6, Pages (June 2003)

Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?

Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells Yuzhi Hong, Wuding Zhou, Ke Li,

Volume 80, Issue 9, Pages (November 2011)

Prediction in idiopathic membranous nephropathy

Volume 60, Issue 2, Pages (August 2001)

Presentation transcript:

Volume 58, Issue 2, Pages 783-789 (August 2000) Impact of interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphism on IgA nephropathy Kuo-Hsiung Shu, Shen-Huey Lee, Chi-Hung Cheng, Ming-Ju Wu, Jong-Da Lian Kidney International Volume 58, Issue 2, Pages 783-789 (August 2000) DOI: 10.1046/j.1523-1755.2000.00227.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Electrophoresis of the polymerase chain reaction (PCR) product of the interleukin-1 receptor antagonist (IL-1ra) gene. Lanes 1, 2, 3, and 5 are four-repeat (410 bp) homozygotes. Lane 4 is a heterozygote of four repeats and three repeats (325 bp). Lane 6 is a heterozygote of four repeats and two repeats (240 bp). M = DNA marker ladder. Kidney International 2000 58, 783-789DOI: (10.1046/j.1523-1755.2000.00227.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Electrophoresis of the PCR product of the tumor necrosis factor-α (TNF-α) gene. Lanes 1 and 5 are homozygotes of TNF1 (-308G). Lane 3 is a homozygote of TNF2 (308A), and lanes 2 and 4 are heterozygotes of TNF1 and TNF2. Kidney International 2000 58, 783-789DOI: (10.1046/j.1523-1755.2000.00227.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Carriage rate of TNF2 (-308A) in different subgroups of IgA nephropathy (IgAN) patients. A significantly higher rate was observed in patients with a history of gross hematuria (GH). Abbreviations are: prog, progressors; nonprog, nonprogressors. Kidney International 2000 58, 783-789DOI: (10.1046/j.1523-1755.2000.00227.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Renal survival analysis in IgAN patients with or without TNF2. There was no significant difference between TNF2 (+) (dashed line) and TNF2 (-) (solid line) patients. The numbers on the graph represent numbers of patients remaining at each time point. Kidney International 2000 58, 783-789DOI: (10.1046/j.1523-1755.2000.00227.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 5 Renal survival analysis in IgAN patients with (solid line) or without (dashed line) IL1RN*2. Patients carrying IL1RN*2 were associated with a significantly shorter length of long-term survival; the median survival time for IL1RN*2(-) was 134 months and for IL1RN*2(+) was 72 months. Kidney International 2000 58, 783-789DOI: (10.1046/j.1523-1755.2000.00227.x) Copyright © 2000 International Society of Nephrology Terms and Conditions